A Confirmatory Study for Evaluation of the Treatment by the Celluma3 of Periorbital Wrinkles

September 4, 2015 updated by: BioPhotas
The primary objective of this study is to confirm the safe and effective use of the Celluma3 for the reduction in the appearance of periorbital wrinkles.

Study Overview

Status

Completed

Conditions

Detailed Description

This clinical study is an open label investigation into the use of the Celluma3 for the effective treatment of periorbital wrinkles.

Test subjects will visit a study center for thirty minute treatments, three times per week, for a period of four weeks, and a twelve week post-treatment follow up after the final treatment. Test subjects will have photos taken at the start, at the end of the four week treatment, and at the final twelve week post-treatment follow up visit.

One of the three Clinical Investigators, will act as the Principal Investigator and all three Clinical Investigators will evaluate the test subjects for inclusion and final results. The Clinical Research Associate (CRA) will monitor the study for conformance to the test protocol.

There will be seven estheticians participating in the study and there will be fifty test subjects recruited.

Study Type

Observational

Enrollment (Actual)

42

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Test subjects will be between the ages of 30-75, Type I-IV Fitzpatrick Skin Color, and willingness and ability to participate and comply with the test protocol and absence of exclusionary criteria.

Description

Inclusion Criteria:

  1. 30-75 years of age
  2. Fitzpatrick Skin Color Type I-IV
  3. Clinical evidence of mild to moderate facial wrinkles as specified by the Fitzpatrick Classification of Facial Wrinkling (Perioral and Periorbital) for the degree of wrinkling and elastosis.
  4. Willingness and ability to comply with the protocol requirements, including returning for follow up visits and abstaining from excluded behaviors for the duration of the study.
  5. Willingness and ability to provide written consent for use of photographic record and adherence to photographic procedures (i.e., removal of makeup and jewelry).
  6. Willingness and ability to provide written informed consent prior to any study-related procedure.
  7. Absence of any of the exclusionary criteria

Exclusion Criteria:

  1. Subject who is pregnant, nursing, or planning to become pregnant during the course of the study.
  2. Subjects who have any history of diabetes.
  3. Subjects who, in the preceding 12 months prior to the study start, have:

    1. Been exposed to hyaluronic acid, or
    2. any other filler, or
    3. injection for cosmetic purposes related to the face, or
    4. undergone any cosmetic procedure for the face, or
    5. had an active cut, wound or infection of the face, or
    6. had oral isotretinon.
  4. Subjects who, in the preceding six months prior to the study start, have:

    1. Had any botulinum toxin ("Botox"), or
    2. had ablative skin resurfacing on the glabellar area.
  5. Subjects who, in the preceding three months prior to the study start, have:

    1. Had retinoid, microdermabrasion or prescription level glycolic acid treatments, or
    2. had any compromising procedure in the opinion of any clinical evaluator.
  6. Any other diagnosis of any contraindication in the current User Manual.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction of Periorbital Wrinkles
Time Frame: 16 weeks
4 weeks of treatment and 12 week follow-up post treatment
16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Jesse Mitchell, MD, FAAD

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2015

Primary Completion (Actual)

August 1, 2015

Study Completion (Actual)

August 1, 2015

Study Registration Dates

First Submitted

September 4, 2015

First Submitted That Met QC Criteria

September 4, 2015

First Posted (Estimate)

September 9, 2015

Study Record Updates

Last Update Posted (Estimate)

September 9, 2015

Last Update Submitted That Met QC Criteria

September 4, 2015

Last Verified

September 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • RLE-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Wrinkled Structure

Subscribe